sun pharma q4: revenue at ₹11,983 cr, misses est, net profit above est at ₹2,654.5 cr | cnbc tv18
Published 3 months ago • 1.9K plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
1:25
sun pharma q1fy25: net profit, ebitda, margin beat est; us formulation sales at $466 m | cnbc tv18
-
1:47
sun pharma q4 preview: strong growth in specialty biz likely to boost q4 performance | cnbc tv18
-
5:25
sun pharma q4 profit rises 7%; beats estimates | #4qwithcnbctv18
-
1:19
sun pharma misses the mark in q4
-
7:16
watch cnbc tv18 live | sun pharma beats the street with ₹1,984 crore net profit in q4fy23
-
1:10:17
chhaap by shivani brings you smart cotton linen digital print suits & muslin chinon party wear suits
-
21:23
editors discuss the week gone by & road ahead for the markets | editor's roundtable | cnbc tv18
-
2:03
us consumer sentiment rises to four-month high
-
1:23
#earningsminute: sun pharma misses street estimates this q4
-
1:43
sun pharma q4 results: india's largest drugmaker reports net profit of rs 1,985 crore
-
6:49
sun pharma's buyout plans & q4 numbers | cs muralidharan explains | business news
-
1:23
sun pharma is a buying opportunity and you must keep it: sudarshan sukhani | cnbc tv18
-
4:07
sun pharma's q3 net profit rises 5% yoy, board approves interim dividend | midcap radar | cnbc-tv18
-
0:35
sun pharma q4 profit in line with estimates
-
13:06
india's earnings hereon will be driven by topline growth: nirmal bang | cnbc tv18
-
2:51
sun pharma q1 net profit drops 46% sequentially
-
6:39
sun pharma reports a largely in-line set of q4 numbers; us sales come in at $430 m | cnbc tv18
-
2:16
sun pharma's halol facility receives u.s. fda warning letter | business lunch | cnbc-tv18
-
2:56
sun pharma, gland pharma, zomato are key stocks in focus | bazaar open exchange | cnbc-tv18
-
4:29
tech mahindra's q2 net profit falls 4% to ₹1,285 crore; sun pharma's q2 net profit up 11%
-
2:26
here are key expectations from sun pharma's q3fy23 earnings | halftime report | cnbc-tv18
-
0:30
sales decline in q4 is a reflection of the pricing pressure in the us generic market: sun pharma